UNICA IRIS Institutional Research Information System

PRETTA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 36.367
NA - Nord America 2.965
AS - Asia 2.517
SA - Sud America 357
AF - Africa 67
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 42.280
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 35.417
US - Stati Uniti d'America 2.852
SG - Singapore 1.033
CN - Cina 702
BR - Brasile 268
VN - Vietnam 267
SE - Svezia 220
DE - Germania 154
FR - Francia 121
FI - Finlandia 108
HK - Hong Kong 103
GB - Regno Unito 101
IN - India 99
NL - Olanda 75
CA - Canada 56
KR - Corea 46
MX - Messico 37
BD - Bangladesh 32
TR - Turchia 32
IQ - Iraq 30
PL - Polonia 25
AT - Austria 23
ZA - Sudafrica 23
AR - Argentina 22
ES - Italia 22
JP - Giappone 22
IE - Irlanda 20
PH - Filippine 19
CO - Colombia 17
EC - Ecuador 17
AE - Emirati Arabi Uniti 16
PK - Pakistan 15
IR - Iran 14
UZ - Uzbekistan 14
VE - Venezuela 14
ID - Indonesia 13
RU - Federazione Russa 13
BE - Belgio 12
SA - Arabia Saudita 11
UA - Ucraina 11
MA - Marocco 10
LT - Lituania 8
CL - Cile 7
KE - Kenya 7
TH - Thailandia 7
AU - Australia 6
GR - Grecia 6
TN - Tunisia 6
IL - Israele 5
NP - Nepal 5
BO - Bolivia 4
CH - Svizzera 4
CZ - Repubblica Ceca 4
EG - Egitto 4
KG - Kirghizistan 4
PY - Paraguay 4
AZ - Azerbaigian 3
BZ - Belize 3
CR - Costa Rica 3
DZ - Algeria 3
JM - Giamaica 3
NG - Nigeria 3
NO - Norvegia 3
OM - Oman 3
PA - Panama 3
PE - Perù 3
PT - Portogallo 3
TW - Taiwan 3
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
GA - Gabon 2
HR - Croazia 2
HU - Ungheria 2
KZ - Kazakistan 2
LB - Libano 2
LU - Lussemburgo 2
LV - Lettonia 2
MK - Macedonia 2
MN - Mongolia 2
MU - Mauritius 2
MY - Malesia 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AL - Albania 1
BG - Bulgaria 1
BJ - Benin 1
CI - Costa d'Avorio 1
DM - Dominica 1
ET - Etiopia 1
HN - Honduras 1
JO - Giordania 1
KH - Cambogia 1
LK - Sri Lanka 1
LY - Libia 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
Totale 42.274
Salva come PNG Salva come JPEG
Città #
Cagliari 33.200
Uta 1.832
Singapore 632
Dallas 526
Ashburn 425
San Jose 271
Boardman 164
Beijing 137
Los Angeles 121
Nyköping 104
Hong Kong 96
Chandler 89
Ho Chi Minh City 88
Fairfield 85
Hefei 77
New York 75
Helsinki 71
Santa Clara 68
The Dalles 65
Hanoi 54
Amsterdam 52
Shanghai 50
Rome 48
Lauterbourg 45
Seoul 45
Council Bluffs 44
Orem 44
Houston 40
Frankfurt am Main 39
Seattle 36
Florence 35
Munich 35
Nuremberg 33
Wilmington 33
São Paulo 31
Redondo Beach 30
Boston 29
Cambridge 28
Guangzhou 28
Woodbridge 26
Chennai 25
Buffalo 24
Montreal 23
Pune 22
Lappeenranta 21
Chicago 20
London 19
Milan 19
Warsaw 19
San Diego 18
Scandicci 18
Stockholm 18
Dublin 17
Manchester 17
Toronto 17
Shenzhen 16
Turku 15
Düsseldorf 14
Johannesburg 14
Mexico City 14
Poplar 14
Tashkent 14
Denver 13
Tokyo 13
Selargius 12
Rio de Janeiro 11
Baghdad 10
Haiphong 10
Paris 10
Vienna 10
Brooklyn 9
Da Nang 9
Dubai 9
Istanbul 9
Tianjin 9
Wuhan 9
Atlanta 8
Brussels 8
Dong Ket 8
Hangzhou 8
Mumbai 8
New Delhi 8
Quito 8
Roubaix 8
Ankara 7
Riyadh 7
Salt Lake City 7
Turin 7
Zhengzhou 7
Belo Horizonte 6
Biên Hòa 6
Caracas 6
Hải Dương 6
Jacksonville 6
Medellín 6
Ninh Bình 6
Phoenix 6
Querétaro 6
San Francisco 6
Bexley 5
Totale 39.636
Salva come PNG Salva come JPEG
Nome #
BRAF-mutant colorectal cancer, a different breed evolving 3.242
Molecular-biology-driven treatment for metastatic colorectal cancer 2.771
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.364
New therapeutic targets in pancreatic cancer 1.634
Immunotherapy and Cancer: The Multi-Omics Perspective 1.609
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.539
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.357
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.222
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world 1.192
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.074
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue 1.043
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 987
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 959
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 959
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 934
Balance between the stem cell marker CD44 and CDX2 expression in colorectal cancer 934
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 899
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 868
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 786
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 775
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? 741
Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer 732
Uncovering key targets of success for immunotherapy in pancreatic cancer 720
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 676
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 671
Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy 652
BRCA-mutant pancreatic ductal adenocarcinoma 618
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 596
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 593
Immune Checkpoint Inhibitors in the Treatment of HCC 590
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 586
Primary adrenal insufficiency induced by immune checkpoint inhibitors: Biological, clinical, and radiological aspects 529
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 476
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 452
Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon 435
CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects 379
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 348
Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas 348
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score 334
Artificial Intelligence Models for the Detection of Microsatellite Instability from Whole-Slide Imaging of Colorectal Cancer 302
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 295
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 276
CD44: A New Prognostic Marker in Colorectal Cancer? 272
A new prognostic score for biliary tract cancer: a multicenter experience 218
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 210
Early taxane exposure and neurotoxicity in breast cancer patients 203
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 199
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 199
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients 192
Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience 183
Cancer-associated fibroblasts (CAFs) and plaque-associated fibroblasts (PAFs): Unraveling the cellular crossroads of atherosclerosis and cancer 181
Medical management of malignant bowel obstruction: our center experience 173
Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors 172
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions 170
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 170
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer 117
Exercise Prescription in Cardio-Oncology 117
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma 106
The impact of surgical resection in early onset colorectal cancer patients with liver limited disease 103
Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study 103
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile 102
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 100
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line 100
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma 94
The correlation between L1CAM expression and outcomes in patients with metastatic colorectal cancer treated with first-line chemotherapy 93
The role of metastasectomy in patients with early onset metastatic colorectal cancer 91
The impact of the fetal exposome as a predictor of cancer risk in childhood and adulthood. Aberrant epigenetic events occurring during gestation: May they trigger fetal programming of cancer risk later in life? 89
Predicability of PD-L1 expression in cancer cells based solely on H&E-stained sections 60
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon 58
Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial 35
Treatment compliance in early-stage anal cancer 33
Abstract 28: Prognostic value of baseline and early changes of circulating cell-free (cf)DNA in the neoadjuvant setting of early stage colon cancer (CC) 20
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel 14
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial 14
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials 12
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer 11
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer 10
Totale 42.521
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.809
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.809
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021703 0 0 0 0 0 0 0 0 0 289 252 162
2021/20222.042 127 87 24 97 119 135 96 187 170 229 334 437
2022/20235.037 400 643 563 372 376 438 226 391 428 528 441 231
2023/20245.556 261 184 185 280 429 859 960 424 371 351 576 676
2024/202517.561 5.035 5.672 1.555 1.659 786 1.105 805 104 197 185 149 309
2025/20266.748 499 410 791 646 535 509 1.497 810 473 578 0 0
Totale 42.521